• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

kanta.subbarao@unimelb.edu.au

Credentials


Position
Honorary (Professorial Fellow)
Department of Microbiology and Immunology
ORCID

0000-0003-1713-3056

Prof Kanta Subbarao

Honorary (Professorial Fellow)
Department of Microbiology and Immunology

417 Scholarly works
64 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59
    DOI: 10.1038/s41541-025-01355-y
  • 2026

    Journal article

    Delivery of monoclonal antibodies using mRNA lipid nanoparticles confers protection against SARS-CoV-2 and influenza
    DOI: 10.1016/j.omtn.2026.102873
  • 2026

    Journal article

    Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia
    DOI: 10.1016/j.jinf.2026.106727
  • 2026

    Journal article

    Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial
    DOI: 10.1093/infdis/jiaf568
  • 2024

    Research contracts (non-grants)

    Leyden SARS2/NL63 Block Contract - Assessment of the Antiviral Agents Against SARS-CoV-2 and Human Coronavirus NL63
  • 2024

    Research grants (international)

    Development of a Novel Long Acting Pan-Influenza Antiviral Drug
  • 2020

    Research grants (ARC, NHMRC, MRFF)

    Translating Virus Biology and Host Immunity for Influenza Control
Kanta Subbarao

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Nomenclature for Tracking of Genetic Variation of Seasonal Influenza Viruses
    DOI: 10.1111/irv.70230
  • 2026

    Journal article

    Antibody responses following COVID-19 vaccination and breakthrough infections in naïve and convalescent individuals suggest imprinting to the ancestral strain of SARS-CoV-2
    DOI: 10.1128/mbio.03221-25
  • 2025

    Journal article

    Modelling the joint effects of single occupancy and N95 respirators on COVID-19 outbreaks in hospital wards
    DOI: 10.1016/j.jhin.2025.06.014
  • 2025

    Journal article

    Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus
    DOI: 10.1038/s44298-025-00116-x
  • 2025

    Journal article

    Accomplishments and challenges in developing improved influenza vaccines: An evaluation of three years of progress toward the milestones of the influenza vaccines research and development roadmap
    DOI: 10.1016/j.vaccine.2025.127431
  • 2025

    Journal article

    Genetic markers of enhanced functional antibody responses to COVID-19 vaccination
    DOI: 10.1016/j.vaccine.2025.127379

RECENT PROJECTS

  • 2025

    Research grants (other domestic)

    Developing CRISPR Cas13 Antiviral Therapeutics for Respiratory Pathogens of Pandemic Potential
  • 2025

    Research grants (ARC, NHMRC, MRFF)

    Assessing the Pandemic Threat of Highly Pathogenic Avian Influenza a Viruses

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224